Sensor
One L-DOPA sensor
A subcutaneous single-microneedle enzymatic electrochemical sensor continuously outputs interstitial L-DOPA curves for objective drug-concentration evidence.
02 / Product architecture
A technology breakthrough moves Parkinson's dosing from experience to data.
DopaMatch is not a standalone hardware idea. It combines an L-DOPA sensor, the MatchPD AI data ecosystem, and a data flywheel.
MatchPD AI data ecosystem
One data ecosystem entry point
Pharma real-world research：Continuous drug concentration and movement data support RWE studies. / Hospital workflow：Home-state signals become continuous curves and visit-ready reports. / Patient daily use：Symptoms, dosing, movement, and concentration changes enter one daily loop. / Academic real-world research：Structured data supports long-term PD medication and motor-complication studies.
Data flywheel
One data flywheel
Real-time drug concentration, movement sensors, and behavior logs calibrate each other to build an increasingly complete drug-motor axis.
Drug-motor axis
Objective drug-motor axis
The key difference is not measuring concentration alone. It is binding real-time drug concentration to patient motor status so clinicians can see how pharmacokinetics map to function.
02B / MatchPD AI data ecosystem
One data ecosystem entry point
The key difference is not measuring concentration alone. It is binding real-time drug concentration to patient motor status so clinicians can see how pharmacokinetics map to function.
01
Pharma real-world research
Continuous drug concentration and movement data support RWE studies.
02
Hospital workflow
Home-state signals become continuous curves and visit-ready reports.
03
Patient daily use
Symptoms, dosing, movement, and concentration changes enter one daily loop.
04
Academic real-world research
Structured data supports long-term PD medication and motor-complication studies.
02C / System value
Objective drug-motor axis
The key difference is not measuring concentration alone. It is binding real-time drug concentration to patient motor status so clinicians can see how pharmacokinetics map to function.
Research · Validation and PoC
Research Edition
Focused on research validation and PoC, proving the continuous biosensor pathway first.
Clinical · Clinical continuous monitoring
Clinical Edition
Links concentration feedback, movement data, and visit reports for clinical continuous monitoring scenarios.
Medical · Medicalization and multimodal sensing
Medical Edition
Moves toward medical-device validation and multimodal sensing, preserving an expandable small-molecule monitoring platform.
03 / Closed-loop technology stack
A full-stack loop across AI, wet lab, and hardware.
The core capability is not a single model or sensor. It is an engineering loop from data, design, wet-lab validation, and hardware acquisition.
Biosensing / computational biology
- AI-assisted directed evolution algorithms
- Structure prediction and protein language models
- Standardized data engineering and private datasets
- In-house protein mutation generation algorithms
- Dry-wet closed-loop validation system
- Continuous L-DOPA monitoring
- Continuous creatinine monitoring
- GZMK binder design for ELISA
- Odorant-binding protein design
- GPCR Exoframe Modulator design
Hardware technology stack
- Software-hardware co-development
- Mixed-signal circuit design
- Full-stack embedded-system design and validation
- Wireless IoT technology
- Wearable-device design validation
- Coin-sized electrochemical front end
- High-precision miniature electrochemical measurement platform
- In-house integrated AFE
- Multichannel parallel acquisition
- AI real-time signal processing and drift compensation
- EIS capability expansion
Future R&D pipeline
- Cortisol
- Homocysteine
- Vancomycin
- Tacrolimus
- 5-fluorouracil
- Atrial natriuretic peptide
04 / Platform
DopaMatch is the start. The closed-loop platform turns one biomarker into multi-target capability.
The same AI design, wet-lab validation, and miniature electrochemical hardware stack can be reused across different small-molecule targets instead of rebuilding the system target by target.
P0 · 2025–2028
L-DOPA
Continuous / PoC complete
P0 · 2025–2027
Homocysteine (Hcy)
POCT / Principle validated
P1 · 2027+
Vancomycin
Continuous TDM / Concept design
P1 · 2027+
Tacrolimus
Continuous TDM / Concept design
P2 · 2028+
Cortisol
POCT / continuous / Literature review
Target roadmap
Go deep in Parkinson's first, then broaden the small-molecule platform.
We start with continuous L-DOPA monitoring, then extend the same platform into kidney function, hormones, TDM, and cardiovascular small molecules.
| Priority | Target | Why it matters | Format | Stage | Timeline |
|---|---|---|---|---|---|
| P0 | L-DOPA | Key to Parkinson's therapy | Continuous monitoring | Animal-study prep | 2026 |
| P1 | Creatinine | Important marker for kidney-function monitoring and chronic care | Continuous monitoring | R&D validation | 2026+ |
| P1 | Cortisol | Core stress and metabolic hormone; circadian rhythm requires continuous capture | POCT / continuous | Pipeline design | 2027+ |
| P1 | Vancomycin | Core ICU anti-infective with a narrow therapeutic window requiring real-time TDM | Continuous monitoring | Pipeline design | 2027+ |
| P1 | Tacrolimus | Core anti-rejection drug for organ transplants; large interpatient variability | Continuous monitoring | Pipeline design | 2027+ |
| P2 | Homocysteine | Independent cardiovascular and cerebrovascular risk factor for high-throughput screening | POCT | Pipeline design | 2028+ |
| P2 | 5-FU / ANP | Future expansion for oncology TDM and cardiovascular-state monitoring | TDM / POCT | Concept design | 2029+ |
CTA
Talk to us.
We are looking for first-cohort research-edition customers (CROs, pharma, academic labs) and neurology KOLs.